The global orally disintegrating tablet (ODT) market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). According to the US Food and Drug Administration (FDA), ODT’s are a solid dosage form that contains a medicinal substance or active ingredient which rapidly disintegrates when placed upon the tongue within a second. The major factor for the growth of the global orally disintegrating tablet (ODT) market during the forecast period is the increasing demand for these tablets due to ease of use and new product launches.

For instance, in February 2022, Dr Reddy’s Laboratories Ltd. along with its subsidiaries announced the launch of Lansoprazole DR Orally Disintegrating Tablets. These tablets are a therapeutic equivalent generic version of Prevacid SoluTab delayed-release orally disintegrating tablets, 15 mg and 30 mg, which is approved by the US FDA. Additionally, in July 2021, SPI Pharma launched UltraBurst an orally disintegrating tablet (ODT). Ultrabrust is an innovative excipient platform for flash ODTs, which disintegrate in under ten seconds. Furthermore, in December 2021, Edenbridge Pharmaceuticals, LLC announced the approval of its New Drug Application (NDA) for DARTISLA ODT (glycopyrrolate) orally disintegrating tablets from the US FDA. DARTISLA ODT is an orally disintegrating tablet available in 1.7 mg for the treatment of peptic ulcers in adults.

Some major players in the market include Teva Pharmaceutical Industries Ltd., Merck KGaA, and Mylan N.V., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in November 2021, Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc. announced a strategic commercialization arrangement for rimegepant in markets outside of the US. Rimegepant is commercialized as Nurtec ODT in the US and is used for the treatment of episodic migraine in adults. 

Market Coverage

    • The market number available for – 2020-2027

    • Base year- 2020

    • Forecast period- 2021-2027

    • Segment Covered- 

o By Drug Class

o By Disease Indication

o By Distribution Channel

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

    • Competitive Landscape- Teva Pharmaceutical Industries Ltd., Merck KGaA, and Mylan N.V., among others.

Key questions addressed by the report

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How players are addressing challenges to sustain growth?

    • Where is the investment opportunity?

Global Orally Disintegrating Tablet (ODT) Market Report by Segment

By Drug Class

    • Anti-Psychotics

    • Anti-Epileptics

    • CNS Stimulants

    • Anxiolytics

    • Anti-Parkinsonian Drugs

    • NSAIDS

    • Anti-Allergy Drugs

    • Others

By Disease Indication

    • CNS Diseases

    • GI Diseases

    • CVS Disorders

    • Allergy

    • Others

By Distribution Channel

    • Hospital Pharmacies

    • Retail Pharmacies

    • Drug Stores

    • Online Pharmacies

Global Orally Disintegrating Tablet (ODT) Market Report by Region

North America

    • United States

    • Canada

Europe

    • UK

    • Germany

    • Italy

    • Spain

    • France

    • Rest of Europe 

Asia-Pacific

    • China

    • India

    • Japan

    • South Korea

    • Rest of Asia-Pacific 

Rest of the World

    • Latin America 

    • Middle East & Africa